A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment
Phase of Trial: Phase II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Cotadutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors MedImmune
- 14 Feb 2019 Status changed from active, no longer recruiting to completed.
- 03 Jan 2019 Planned End Date changed from 1 Feb 2019 to 8 Feb 2019.
- 03 Jan 2019 Planned primary completion date changed from 1 Feb 2019 to 8 Feb 2019.